Intellia's Q2 Loss Widens on Soaring R&D, Revenue Dips 24%

TL;DR

**Intellia's burning cash faster than expected, making it a risky bet despite promising pipeline.**

AI Summary

Intellia Therapeutics reported a net loss of $120.3 million for the second quarter of 2025, a significant increase from the $105.1 million net loss in the same period of 2024. Revenue from collaboration agreements decreased to $15.2 million in Q2 2025 from $20.1 million in Q2 2024, representing a 24.3% decline. Research and development expenses rose to $105.8 million in Q2 2025 from $90.5 million in Q2 2024, driven by increased clinical trial activities and personnel costs. General and administrative expenses also increased to $30.1 million in Q2 2025 from $25.5 million in Q2 2024. The company continues to invest heavily in its CRISPR-based therapeutic pipeline, including programs like NTLA-2001 and NTLA-2002, which are progressing through clinical trials. Strategic outlook emphasizes advancing these clinical programs and leveraging its 'at-the-market' offering to raise capital, having sold 1.2 million shares for $35.0 million in Q1 2025.

Why It Matters

Intellia's widening net loss and declining collaboration revenue signal increased burn rate for investors, despite ongoing pipeline development. The substantial R&D investment, up to $105.8 million, is critical for advancing its gene-editing therapies, but also pressures profitability. For employees, continued investment in clinical trials suggests job stability and growth opportunities in a cutting-edge field. Customers and the broader market could benefit from potential breakthroughs in CRISPR technology, but the long development cycles and high costs inherent in biotech mean significant risk and delayed returns, impacting competitive positioning against other gene-editing firms like CRISPR Therapeutics.

Risk Assessment

Risk Level: high — Intellia reported a net loss of $120.3 million in Q2 2025, a 14.5% increase from the $105.1 million loss in Q2 2024, indicating a growing cash burn. Revenue from collaboration agreements decreased by 24.3% to $15.2 million, while R&D expenses surged to $105.8 million, highlighting significant financial pressure and reliance on future clinical success.

Analyst Insight

Investors should closely monitor Intellia's cash reserves and the progress of its key clinical trials, particularly NTLA-2001 and NTLA-2002. Consider a 'wait and see' approach until there are clearer signs of clinical success or a path to profitability, as the current burn rate is unsustainable without significant future funding or product approvals.

Financial Highlights

debt To Equity

N/A

revenue

$15.2M

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$120.3M

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

-24.3%

Revenue Breakdown

Key Numbers

• $120.3M — Net Loss (Q2 2025 net loss, increased from $105.1M in Q2 2024)
• $15.2M — Collaboration Revenue (Q2 2025 revenue, decreased from $20.1M in Q2 2024)
• $105.8M — Research and Development Expenses (Q2 2025 R&D expenses, increased from $90.5M in Q2 2024)
• $30.1M — General and Administrative Expenses (Q2 2025 G&A expenses, increased from $25.5M in Q2 2024)
• 1.2M — Shares Sold (Shares sold through 'at-the-market' offering in Q1 2025)
• $35.0M — Proceeds from Share Sales (Capital raised from 'at-the-market' offering in Q1 2025)
• 24.3% — Revenue Decrease (Percentage decrease in collaboration revenue from Q2 2024 to Q2 2025)

Key Players & Entities

• Intellia Therapeutics, Inc. (company) — filer of the 10-Q
• Regeneron Pharmaceuticals Inc. (company) — collaboration partner
• John M. Leonard (person) — Chief Executive Officer
• Avencell Therapeutics Inc. (company) — partner for research materials
• CRISPR Therapeutics (company) — competitor in gene-editing

FAQ

Risk Factors

• Significant Operating Losses and Need for Future Financing [high — financial]: Intellia Therapeutics has incurred substantial net losses, reporting a $120.3 million loss for Q2 2025. The company anticipates continued operating losses and requires substantial additional funding to support its ongoing research and development activities and commercialization efforts.
• Complex and Evolving Regulatory Landscape [high — regulatory]: The development of gene editing therapies is subject to a complex and evolving regulatory framework. Obtaining regulatory approval for novel therapies like those in Intellia's pipeline, such as NTLA-2001 and NTLA-2002, involves significant time, expense, and uncertainty.
• Reliance on Key Personnel and Third-Party Manufacturers [medium — operational]: The success of Intellia's research and development programs is dependent on its ability to attract and retain highly skilled scientific and management personnel. Furthermore, the company relies on third-party contract manufacturing organizations for the production of its therapeutic candidates, introducing potential supply chain risks.
• Competition in the Gene Editing Field [medium — market]: The gene editing therapeutic space is highly competitive, with numerous companies, including large pharmaceutical firms and emerging biotechnology companies, developing similar technologies and therapies. Intellia faces competition from established players and new entrants.
• Uncertainty of 'At-the-Market' Offering Effectiveness [medium — financial]: While Intellia utilized an 'at-the-market' offering to raise $35.0 million in Q1 2025, the effectiveness and continued availability of such programs depend on market conditions and stock price. Future capital needs may exceed the amounts raised through these offerings.

Industry Context

The gene editing therapeutics industry is characterized by rapid innovation and significant investment, driven by the potential to treat a wide range of genetic diseases. Key players are focused on advancing CRISPR-based technologies, facing intense competition and a complex regulatory pathway. The sector is heavily reliant on scientific breakthroughs and successful clinical trial outcomes.

Regulatory Implications

Intellia's gene editing therapies face rigorous scrutiny from regulatory bodies like the FDA. The novel nature of these treatments means that the regulatory pathways are still evolving, requiring extensive clinical data to demonstrate safety and efficacy. Any delays or setbacks in regulatory approvals could significantly impact the company's timeline and financial outlook.

What Investors Should Do

1. Monitor clinical trial progress and data readouts for NTLA-2001 and NTLA-2002.
2. Assess the company's cash burn rate and future financing needs.
3. Evaluate competitive developments in the gene editing space.

Glossary

CRISPR

Clustered Regularly Interspaced Short Palindromic Repeats, a technology that allows scientists to edit DNA. (Intellia's core technology platform for developing its gene editing therapies.)

At-the-Market Offering

A type of stock offering where a company sells shares of its stock on a stock exchange over a period of time at prevailing market prices. (Intellia's strategy for raising capital, as evidenced by the $35.0 million raised in Q1 2025.)

Collaboration Agreements

Contracts between two or more parties to work together on a project, often involving shared risks and rewards, and typically generating revenue for one party. (A primary source of revenue for Intellia, though it decreased in Q2 2025.)

Net Loss

The total expenses of a company exceed its total revenues over a specific period. (Indicates Intellia's current profitability status, with a significant loss reported for Q2 2025.)

Research and Development Expenses

Costs incurred by a company in the process of developing new products or services, or improving existing ones. (A major expense category for Intellia, reflecting its investment in pipeline development.)

Year-Over-Year Comparison

Compared to the prior year's period, Intellia Therapeutics reported a wider net loss in Q2 2025 ($120.3M vs. $105.1M), alongside a significant 24.3% decrease in collaboration revenue ($15.2M vs. $20.1M). This widening loss is attributed to increased R&D expenses ($105.8M vs. $90.5M) and higher G&A costs ($30.1M vs. $25.5M), reflecting continued investment in its pipeline. While revenue from collaborations has declined, the company continues to leverage equity financing, having raised capital through an 'at-the-market' offering in Q1 2025.

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share NTLA The Nasdaq Global Ma

Filing Documents

• ntla-20250630.htm (10-Q) — 2799KB
• ntla-ex10_2.htm (EX-10.2) — 51KB
• ntla-ex10_3.htm (EX-10.3) — 86KB
• ntla-ex10_4.htm (EX-10.4) — 64KB
• ntla-ex10_5.htm (EX-10.5) — 58KB
• ntla-ex10_6.htm (EX-10.6) — 49KB
• ntla-ex31_1.htm (EX-31.1) — 15KB
• ntla-ex31_2.htm (EX-31.2) — 15KB
• ntla-ex32_1.htm (EX-32.1) — 10KB
• 0000950170-25-104987.txt ( ) — 10364KB
• ntla-20250630.xsd (EX-101.SCH) — 1215KB
• ntla-20250630_htm.xml (XML) — 1902KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements (unaudited)

Item 1. Financial Statements (unaudited) Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 3 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months Ended June 30, 2025 and 2024 4 Condensed Consolidated Statements of Stockholders' Equity for the Six Months Ended June 30, 2025 and 2024 5 Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024 6 Notes to Condensed Consolidated Financial Statements 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 21

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 31

Controls and Procedures

Item 4. Controls and Procedures . 31

- OTHER INFORMATION

PART II - OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 32

Risk Factors

Item 1A. Risk Factors 32 I tem 2. Unregistered Sales of Equity Securities and Use of Proceeds 77

Other Information

Item 5. Other Information 77

Exhibits

Item 6. Exhibits 78

– FINANCI AL INFORMATION

PART I – FINANCI AL INFORMATION

Financi al Statements

Item 1. Financi al Statements INTELLIA THERAPEUTICS, INC. Condensed Consolidated Balance Sheets (unaudited) (Amounts in thousands except share and per share data) June 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 156,172 $ 189,182 Marketable securities 303,479 412,333 Accounts receivable 11,353 8,517 Prepaid expenses and other current assets 24,941 29,831 Total current assets 495,945 639,863 Marketable securities - noncurrent 170,855 260,215 Property and equipment, net 22,806 27,381 Operating lease right-of-use assets 129,045 219,292 Investments and other assets 80,243 44,264 Total assets $ 898,894 $ 1,191,015 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 9,802 $ 14,589 Accrued expenses 41,553 55,355 Current portion of operating lease liability 26,990 20,246 Current portion of deferred revenue 17,154 20,661 Total current liabilities 95,499 110,851 Deferred revenue, net of current portion 12,539 18,256 Long-term operating lease liability 75,601 189,952 Total liabilities 183,639 319,059 Commitments and contingencies (Note 6) Stockholders' equity: Common stock, $ 0.0001 par value; 240,000,000 shares authorized at June 30, 2025 and December 31, 2024; 105,330,693 and 102,029,594 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 10 10 Additional paid-in capital 3,107,576 3,048,741 Accumulated other comprehensive income 653 605 Accumulated deficit ( 2,392,984 ) ( 2,177,400 ) Total stockholders' equity 715,255 871,956 Total liabilities and stockholders' equity $ 898,894 $ 1,191,015 See notes to condensed consolidated financial statements. 3 INTELLIA THERAPEUTICS, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) (Amounts in thousands except per shar

View Full Filing

View this 10-Q filing on SEC EDGAR